New publication: Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

November 28, 2018December 5, 2018 imi2_admin

Although there are a growing number of well-reported, late-stage clinical trial failures in Alzheimer’s disease, the introduction of a disease-modifying therapy within the next 5 years may be anticipated.

BD4BO
Big Data for Better Outcomes				Contact for BD4BO Website
This website has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2) under grant agreement No. 116055. This Joint Undertaking receives support from the European Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).				Semmelweis University – Health Services Management Training Centre, Budapest Email: doit.communication@emk.sote.hu Legal notice

Definitions
Big Data	BD4BO
“Big data in health refers to largely routinely or automatically collected datasets, which are electronically captured and stored. It is reusable in the sense of multipurpose data and comprises the fusion and connection of existing databases for the purpose of improving health and health system performance.” (European Commission, Study on Big Data in Public Health, Telemedicine and Healthcare. 2016.)	Big Data for Better Outcomes is a comprehensive European research programme funded by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2) aiming to develop key enablers to support healthcare system transformation through the use of big data.
DO->IT	Core outcome sets
“Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation” is the Coordination and Support Action project of the BD4BO programme.	the agreed minimum standardised set of outcomes that should be measured and reported in trials or other research on a specific condition.